Taligen Therapeutics Appoints Industry Leader, John Maraganore, as Director

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced the appointment of John Maraganore, Ph.D., CEO of Alnylam Pharmaceuticals to its Board of Directors.

Back to news